|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MUTYH |
Gene summary for MUTYH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MUTYH | Gene ID | 4595 |
| Gene name | mutY DNA glycosylase | |
| Gene Alias | MYH | |
| Cytomap | 1p34.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | E5KP27 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4595 | MUTYH | LZE2T | Human | Esophagus | ESCC | 4.73e-03 | 2.93e-01 | 0.082 |
| 4595 | MUTYH | LZE7T | Human | Esophagus | ESCC | 3.98e-06 | 2.34e-01 | 0.0667 |
| 4595 | MUTYH | LZE8T | Human | Esophagus | ESCC | 2.72e-03 | 1.41e-01 | 0.067 |
| 4595 | MUTYH | LZE20T | Human | Esophagus | ESCC | 4.98e-02 | 1.04e-01 | 0.0662 |
| 4595 | MUTYH | LZE21D1 | Human | Esophagus | HGIN | 4.41e-04 | 3.15e-01 | 0.0632 |
| 4595 | MUTYH | LZE22D1 | Human | Esophagus | HGIN | 8.03e-04 | 1.67e-01 | 0.0595 |
| 4595 | MUTYH | LZE24T | Human | Esophagus | ESCC | 2.42e-13 | 3.09e-01 | 0.0596 |
| 4595 | MUTYH | LZE21T | Human | Esophagus | ESCC | 8.02e-04 | 2.15e-01 | 0.0655 |
| 4595 | MUTYH | LZE6T | Human | Esophagus | ESCC | 3.01e-06 | 2.21e-01 | 0.0845 |
| 4595 | MUTYH | P1T-E | Human | Esophagus | ESCC | 2.97e-02 | 1.50e-01 | 0.0875 |
| 4595 | MUTYH | P2T-E | Human | Esophagus | ESCC | 3.36e-15 | 3.43e-01 | 0.1177 |
| 4595 | MUTYH | P4T-E | Human | Esophagus | ESCC | 6.14e-11 | 2.52e-01 | 0.1323 |
| 4595 | MUTYH | P5T-E | Human | Esophagus | ESCC | 2.73e-08 | 2.19e-01 | 0.1327 |
| 4595 | MUTYH | P8T-E | Human | Esophagus | ESCC | 7.13e-06 | 1.51e-01 | 0.0889 |
| 4595 | MUTYH | P10T-E | Human | Esophagus | ESCC | 8.32e-10 | 2.61e-01 | 0.116 |
| 4595 | MUTYH | P11T-E | Human | Esophagus | ESCC | 6.08e-06 | 1.93e-01 | 0.1426 |
| 4595 | MUTYH | P12T-E | Human | Esophagus | ESCC | 7.04e-09 | 1.79e-01 | 0.1122 |
| 4595 | MUTYH | P15T-E | Human | Esophagus | ESCC | 3.34e-06 | 1.66e-01 | 0.1149 |
| 4595 | MUTYH | P16T-E | Human | Esophagus | ESCC | 9.00e-08 | 1.61e-01 | 0.1153 |
| 4595 | MUTYH | P17T-E | Human | Esophagus | ESCC | 8.50e-05 | 2.54e-01 | 0.1278 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006285 | Esophagus | HGIN | base-excision repair, AP site formation | 6/2587 | 12/18723 | 3.03e-03 | 2.88e-02 | 6 |
| GO:00062843 | Esophagus | ESCC | base-excision repair | 33/8552 | 43/18723 | 3.25e-05 | 2.69e-04 | 33 |
| GO:0006304 | Esophagus | ESCC | DNA modification | 68/8552 | 120/18723 | 9.95e-03 | 3.42e-02 | 68 |
| GO:00062842 | Oral cavity | OSCC | base-excision repair | 28/7305 | 43/18723 | 4.71e-04 | 2.79e-03 | 28 |
| GO:00062841 | Oral cavity | LP | base-excision repair | 19/4623 | 43/18723 | 4.04e-03 | 2.61e-02 | 19 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa034104 | Esophagus | ESCC | Base excision repair | 38/4205 | 44/8465 | 3.59e-07 | 2.62e-06 | 1.34e-06 | 38 |
| hsa0341011 | Esophagus | ESCC | Base excision repair | 38/4205 | 44/8465 | 3.59e-07 | 2.62e-06 | 1.34e-06 | 38 |
| hsa03410 | Oral cavity | OSCC | Base excision repair | 32/3704 | 44/8465 | 9.11e-05 | 3.25e-04 | 1.65e-04 | 32 |
| hsa034101 | Oral cavity | OSCC | Base excision repair | 32/3704 | 44/8465 | 9.11e-05 | 3.25e-04 | 1.65e-04 | 32 |
| hsa034102 | Oral cavity | LP | Base excision repair | 23/2418 | 44/8465 | 7.66e-04 | 3.75e-03 | 2.42e-03 | 23 |
| hsa034103 | Oral cavity | LP | Base excision repair | 23/2418 | 44/8465 | 7.66e-04 | 3.75e-03 | 2.42e-03 | 23 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MUTYH | SNV | Missense_Mutation | c.125N>T | p.Asn42Ile | p.N42I | Q9UIF7 | protein_coding | deleterious_low_confidence(0.02) | benign(0.006) | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| MUTYH | SNV | Missense_Mutation | c.921G>C | p.Gln307His | p.Q307H | Q9UIF7 | protein_coding | tolerated(0.19) | benign(0.01) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| MUTYH | SNV | Missense_Mutation | novel | c.142N>T | p.Pro48Ser | p.P48S | Q9UIF7 | protein_coding | tolerated_low_confidence(0.1) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| MUTYH | insertion | Frame_Shift_Ins | novel | c.376_377insACAA | p.Ala126AspfsTer125 | p.A126Dfs*125 | Q9UIF7 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| MUTYH | insertion | Nonsense_Mutation | novel | c.375_376insTTTAGGTGGAGGAGAGAGGAGTCAGATTTGCATTTTTAG | p.Tyr125_Ala126insPheArgTrpArgArgGluGluSerAspLeuHisPheTer | p.Y125_A126insFRWRREESDLHF* | Q9UIF7 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| MUTYH | SNV | Missense_Mutation | rs759822330 | c.910N>T | p.Arg304Trp | p.R304W | Q9UIF7 | protein_coding | tolerated(0.07) | benign(0.061) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| MUTYH | SNV | Missense_Mutation | rs781163298 | c.247C>G | p.Leu83Val | p.L83V | Q9UIF7 | protein_coding | tolerated(0.16) | benign(0) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MUTYH | SNV | Missense_Mutation | rs587782165 | c.442G>A | p.Gly148Arg | p.G148R | Q9UIF7 | protein_coding | tolerated(1) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| MUTYH | SNV | Missense_Mutation | rs587780746 | c.304G>A | p.Asp102Asn | p.D102N | Q9UIF7 | protein_coding | deleterious(0.03) | benign(0.105) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| MUTYH | SNV | Missense_Mutation | c.805C>A | p.Pro269Thr | p.P269T | Q9UIF7 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4595 | MUTYH | DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME | cyclophosphamide | CYCLOPHOSPHAMIDE | 24533712 | |
| 4595 | MUTYH | DNA REPAIR, CLINICALLY ACTIONABLE, ENZYME | cisplatin | CISPLATIN | 24533712 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |